Tsuda S, Matsusaka N, Madarame H, Ueno S, Susa N, Ishida K, Kawamura N, Sekihashi K, Sasaki Y F
Laboratory of Veterinary Public Health, Department of Veterinary Medicine, Faculty of Agriculture, Iwate University, Ueda 3-18-8, Morioka, Japan.
Mutat Res. 2000 Feb 16;465(1-2):11-26. doi: 10.1016/s1383-5718(99)00199-0.
The genotoxicity of 24 azo compounds selected from IARC (International Agency for Research on Cancer) groups 2A, 2B, and 3 were determined by the comet (alkaline single cell gel electrophoresis, SCG) assay in eight mouse organs. We treated groups of four mice once orally at the maximum tolerated dose (MTD) and sampled stomach, colon, liver, kidney, bladder, lung, brain, and bone marrow 3, 8, and 24 h after treatment. For the 17 azo compounds, the assay was positive in at least one organ; (1) 14 and 12 azo compounds induced DNA damage in the colon and liver, respectively, (2) the genotoxic effect of most of them was greatest in the colon, and (3) there were high positive responses in the gastrointestinal organs, but those organs are not targets for carcinogenesis. One possible explanation for this discrepancy is that the assay detects DNA damage induced shortly after administration of a relatively high dose, while carcinogenicity is detected after long treatment with relatively low doses. The metabolic enzymes may become saturated following high doses and the rates and pathways of metabolic activation and detoxification may differ following high single doses vs. low long-term doses. Furthermore, considering that spontaneous colon tumors are very rare in rats and mice, the ability to detect tumorigenic effects in the colon of those animals might be lower than the ability to detect genotoxic events in the comet assay. The in vivo comet assay, which has advantage of reflecting test chemical absorption, distribution, and excretion as well as metabolism, should be effective for estimating the risk posed by azo dyes to humans in spite of the difference in dosage regimen.
采用彗星试验(碱性单细胞凝胶电泳,SCG)测定了从国际癌症研究机构(IARC)2A、2B和3组中选出的24种偶氮化合物在8种小鼠器官中的遗传毒性。我们以最大耐受剂量(MTD)对每组4只小鼠进行一次口服给药,并在给药后3小时、8小时和24小时采集胃、结肠、肝脏、肾脏、膀胱、肺、脑和骨髓样本。对于17种偶氮化合物,该试验在至少一个器官中呈阳性;(1)分别有14种和12种偶氮化合物在结肠和肝脏中诱导DNA损伤,(2)其中大多数的遗传毒性作用在结肠中最为显著,(3)在胃肠道器官中有高阳性反应,但这些器官并非致癌作用的靶器官。对此差异的一种可能解释是,该试验检测的是在给予相对高剂量后不久诱导的DNA损伤,而致癌性是在给予相对低剂量的长期处理后检测到的。高剂量后代谢酶可能会饱和,单次高剂量与长期低剂量后的代谢活化和解毒速率及途径可能不同。此外,考虑到大鼠和小鼠中自发性结肠肿瘤非常罕见,在这些动物的结肠中检测致瘤效应的能力可能低于在彗星试验中检测遗传毒性事件的能力。尽管给药方案存在差异,但体内彗星试验具有反映受试化学物质的吸收、分布、排泄以及代谢的优势,应该能够有效地评估偶氮染料对人类造成的风险。